Chromosome 8p alterations in sporadic and BRCA2 999del5 linked breast cancer
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsSigbjornsdottir, B I
Agnarsson, B A
Barkardottir, R B
MetadataShow full item record
CitationJ. Med. Genet. 2000, 37(5):342-7
AbstractChromosomal losses involving the short arm of chromosome 8 are frequent in a variety of tumour types, including breast cancer, suggesting the presence of one or more tumour suppressor genes in this region. In this study, we have used 11 microsatellite markers to analyse loss of heterozygosity (LOH) at chromosome 8p in 151 sporadic breast tumours and 50 tumours from subjects carrying the BRCA2 999del5 mutation. Fifty percent of sporadic tumours compared to 78% of BRCA2 linked tumours exhibit LOH at one or more markers at 8p showing that chromosome 8p alterations in breast tumours from BRCA2 999del5 carriers are more pronounced than in sporadic breast tumours. The pattern of LOH is different in the two groups and a higher proportion of BRCA2 tumours have LOH in a large region of chromosome 8p. In the total patient material, LOH of 8p is associated with LOH at other chromosome regions, for example, 1p, 3p, 6q, 7q, 9p, 11p, 13q, 17p, and 20q, but no association is found between LOH at 8p and chromosome regions 11q, 16q, 17q, and 18q. Furthermore, an association is detected between LOH at 8p and positive node status, large tumour size, aneuploidy, and high S phase fraction. Breast cancer patients with LOH at chromosome 8p have a worse prognosis than patients without this defect. Multivariate analysis suggests that LOH at 8p is an independent prognostic factor. We conclude that chromosome 8p carries a tumour suppressor gene or genes, the loss of which results in growth advantage of breast tumour cells, especially in carriers of the BRCA2 999del5 mutation.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field
- High incidence of loss of heterozygosity in breast tumors from carriers of the BRCA2 999del5 mutation.
- Authors: Ingvarsson S, Geirsdottir EK, Johannesdottir G, Sigbjörnsdóttir BI, Eiriksdottir G, Ragnarsson G, Agnarsson BA, Gudmundsson J, Jonasson JG, Sigurdsson A, Egilsson V, Barkardottir RB
- Issue date: 1998 Oct 1
- Allelic loss at chromosome 13q12-q13 is associated with poor prognosis in familial and sporadic breast cancer.
- Authors: van den Berg J, Johannsson O, Håkansson S, Olsson H, Borg A
- Issue date: 1996 Nov
- Alterations of the FHIT gene in breast cancer: association with tumor progression and patient survival.
- Authors: Ingvarsson S, Sigbjornsdottir BI, Huiping C, Jonasson JG, Agnarsson BA
- Issue date: 2001
- Mapping loss of heterozygosity at chromosome 13q: loss at 13q12-q13 is associated with breast tumour progression and poor prognosis.
- Authors: Eiriksdottir G, Johannesdottir G, Ingvarsson S, Björnsdottir IB, Jonasson JG, Agnarsson BA, Hallgrimsson J, Gudmundsson J, Egilsson V, Sigurdsson H, Barkardottir RB
- Issue date: 1998 Dec
- High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers.
- Authors: Eiriksdottir G, Barkardottir RB, Agnarsson BA, Johannesdottir G, Olafsdottir K, Egilsson V, Ingvarsson S
- Issue date: 1998 Jan 8